GSK re­ports PhI­II flop for BC­MA drug — rais­ing ques­tions about its fu­ture and up­ping the stakes on com­bos

Two years af­ter an ac­cel­er­at­ed ap­proval, GSK’s BC­MA-tar­get­ing an­ti­body-drug con­ju­gate has flunked a Phase III study in mul­ti­ple myelo­ma, rais­ing doubts about the phar­ma gi­ant …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER